JPMorgan lowered the firm’s price target on Ascendis Pharma to $165 from $174 and keeps an Overweight rating on the shares. The analyst updated the company’s model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- 3 Best Stocks to Buy Now, 9/4/2024, According to Top Analysts
- Ascendis Pharma price target lowered to $264 from $277 at Wells Fargo
- Ascendis Pharma price target lowered to $178 from $193 at Citi
- Closing Bell Movers: GitLab up 14%, Zscaler down 14 after earnings
- Ascendis Pharma Strikes $150M Sales Rights Deal